However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

A new study suggests that one of them, ubrogepant (Ubrelvy), may help people stop a migraine attack from happening when it’s used before the pain begins. A migraine attack is a complex ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

According to the medical journal Neurology, researchers said those who took ubrogepant or Ubrelvy were more than 70 per cent likely to function normally within a couple of hours. The drug was also ...

These healthcare stocks have fantastic dividend track records. In the immortal words of the late, great entertainer Prince, ...

When migraine patients visit AbbVie’s website for Ubrelvy (ubrogepant), a button in the top-right corner of the site offers the option to talk to a doctor. If patients click, they are taken to ...

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...

Your head hurts. Maybe you were staring at your computer or phone too long. Or you skipped breakfast, didn’t sleep well, or got stressed fighting traffic. But now that it’s here, what can you do to ...

Continued, healthy, double-digit Y/Y growth of the neuroscience segment is my baseline assumption, and it should be driven by the two migraine drugs Ubrelvy and Qulipta, and also by continued ...

Other drugs commonly used include a) Gepants, newer medications that target CGRP (calcitonin gene-related peptide); examples - Ubrogepant (Ubrelvy) Rimegepant (Nurtec ODT); b) Ditans, newer ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company’s ...